Saccharomyces boulardii in patients with severe acute pancreatitis: a single center, open-label randomized controlled trial

Abstract

Background: Nosocomial infections in patients with severe acute pancreatitis (SAP) are frequently driven by impaired intestinal barrier function, which facilitates bacterial translocation and contributes to adverse clinical outcomes. Saccharomyces boulardii (S. boulardii) can reconstitute gut microbiota composition. We investigated whether S. boulardii combined with enteral nutrition (EN) affects the microbiome and nosocomial infections in SAP. Methods: This study is a single centre, open-label randomized controlled trial. We included 50 patients with SAP in a Chinese gastroenterology intensive care unit (ICU), randomized to Probiotic group ( S. boulardii and EN) or the Control group (EN). Throat/oropharyngeal and rectal swabs were collected from patients with SAP on days 0, 1, 3, 6, 9, 12, and 15 of ICU admission. The primary endpoints were nosocomial infection and fungemia, whereas the secondary endpoints were ICU mortality, 28-day mortality, ICU stay, and length of hospital stay. All samples were subjected to full-length 16S rRNA and internal transcribed spacer (ITS) sequencing. Multivariate analysis was performed using normalized microbial and corresponding clinical data. Results: After data processing, 213 16S rRNA and 120 ITS samples were analysed. S. boulardii prevented nosocomial infections (0/27 in the Probiotic group vs 5/23 in the Control group; P < 0.05). Intestinal fungi were closely associated with nosocomial infections. Bioinformatic analysis showed that S. boulardii prevented nosocomial infections by reducing intestinal bacterial perturbation and inhibiting the proliferation of Enterococcus in the intestine, and Candida in the respiratory tract and intestines. Conclusions: S. boulardii in patients with SAP may positively alter the respiratory and intestinal microbiome and decrease the incidence of nosocomial infections. Trial registration: This study was approved by the Ethics Committee of Xinqiao Hospital, Army Medical University, Chongqing China (2021-yd030–01), which was retrospectively registered at the Chinese Clinical Trial Registry (ChiCTR2200056011, Date of Registration: 30/01/2022 https://www.chictr.org.cn/showproj.html?proj=151215).

Keywords

Saccharomyces boulardii / Nosocomial infections / Respiratory and intestinal microbiota / Severe acute pancreatitis patients

References

[1] van Dijk SM, Hallensleben NDL, van Santvoort HC, Fockens P, van Goor H, Bruno MJ, et al. Acute pancreatitis: recent advances through randomised trials. Gut. 2017; 66:2024-32. https://doi.org/10.1136/gutjnl-2016-313595.

[2] Shi N, Liu T, de la Iglesia-Garcia D, Deng L, Jin T, Lan L, et al. Duration of organ failure impacts mortality in acute pancreatitis. Gut. 2020; 69:604-5. https://doi.org/10.1136/gutjnl-2019-318241.

[3] Dellinger EP, Forsmark CE, Layer P, Lévy P, Maraví-Poma E, Petrov MS, et al. Determinant-based classification of acute pancreatitis severity: an international multidisciplinary consultation. Ann Surg. 2012; 256:875-80. https://doi.org/10.1097/SLA.0b013e318256f778.

[4] Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, et al. Classification of acute pancreatitis-2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013; 62:102-11. https://doi.org/10.1136/gutjnl-2012-302779.

[5] Trikudanathan G, Yazici C, Evans Phillips A, Forsmark CE. Diagnosis and Management of Acute Pancreatitis. Gastroenterology. 2024; 167:673-688. https://doi.org/10.1053/j.gastro.2024.02.052.

[6] Jabłońska B, Mrowiec S. Nutritional support in patients with severe acute pancreatitis-current standards. Nutrients. 2021; 13:1498. https://doi.org/10.3390/nu13051498.

[7] Sanders ME, Merenstein DJ, Reid G, Gibson GR, Rastall RA. Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. Nat Rev Gastroenterol Hepatol. 2019; 16:605-16. https://doi.org/10.1038/s41575-019-0173-3.

[8] Zeng J, Wang CT, Zhang FS, Qi F, Wang SF, Ma S, et al. Effect of probiotics on the incidence of ventilator-associated pneumonia in critically ill patients: a randomized controlled multicenter trial. Intensive Care Med. 2016; 42:1018-28. https://doi.org/10.1007/s00134-016-4303-x.

[9] Alberda C, Gramlich L, Meddings J, Field C, McCargar L, Kutsogiannis D, et al. Effects of probiotic therapy in critically ill patients: a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr. 2007; 85:816-23. https://doi.org/10.1093/ajcn/85.3.816.

[10] Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2008; 371:651-9. https://doi.org/10.1016/S0140-6736(08)60207-X.

[11] Compher C, Bingham AL, McCall M, Patel J, Rice TW, Braunschweig C, et al. Guidelines for the provision of nutrition support therapy in the adult critically ill patient: the American Society for Parenteral and Enteral Nutrition. J Parenter Enter Nutr. 2022; 46:12-41. https://doi.org/10.1002/jpen.2267.

[12] Arvanitakis M, Ockenga J, Bezmarevic M, Gianotti L, Krznarić Ž, Lobo DN, et al. ESPEN guideline on clinical nutrition in acute and chronic pancreatitis. Clin Nutr. 2020; 39:612-31. https://doi.org/10.1016/j.clnu.2020.01.004.

[13] Ke L, Ye B, Huang M, Chen T, Doig G, Li C, et al. Balanced solution versus normal saline in predicted severe acute pancreatitis: a stepped wedge cluster randomized trial. Ann Surg. 2025; 281:86-94. https://doi.org/10.1097/SLA.0000000000006319.

[14] Ke L, Li G, Mao W, Doig G, Chen T, Li C, et al. Early versus delayed catheter drainage for patients with necrotizing pancreatitis and early persistent organ failure (TIMING): a multicenter randomized controlled trial. Intensive Care Med. 2025; 51:1431-41. https://doi.org/10.1007/s00134-025-08020-x.

[15] Ke L, Zhou J, Mao W, Chen T, Zhu Y, Pan X, et al. Immune enhancement in patients with predicted severe acute necrotising pancreatitis: a multicentre double-blind randomised controlled trial. Intensive Care Med. 2022; 48:899-909. https://doi.org/10.1007/s00134-022-06745-7.

[16] Zhang L, Ke L. Beta blockers in critical illness: promising but appropriate subphenotyping is needed. Burns Trauma. 2024; 12:tkae060. https://doi.org/10.1093/burnst/tkae060.

[17] Lv C, Zhou L, Zhou Y, Lew CCH, Lee ZY, Hasan MS, et al. Early protein delivery in critically ill patients with acute kidney injury: post hoc analysis of a multicenter cluster-randomized controlled trial. Burns Trauma. 2024; 12:tkae027. https://doi.org/10.1093/burnst/tkae027.

[18] Gou S, Yang Z, Liu T, Wu H, Wang C. Use of probiotics in the treatment of severe acute pancreatitis: a systematic review and meta-analysis of randomized controlled trials. Crit Care. 2014; 18:R57. https://doi.org/10.1186/cc13809.

[19] Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011; 12:77. https://doi.org/10.1186/1471-2105-12-77.

[20] Beghini F, McIver LJ, Blanco-Míguez A, Dubois L, Asnicar F, Maharjan S, et al. Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3. eLife. 2021; 10:e65088. https://doi.org/10.7554/eLife.65088.

[21] Langmead B, Salzberg SL. Fast gapped-read alignment with bowtie 2. Nat Methods. 2012;9:357-9. https://doi.org/10.1038/nmeth.1923.

[22] Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014; 30:2114-20. https://doi.org/10.1093/bioinformatics/btu170.

[23] Buchfink B, Xie C, Huson DH. Fast and sensitive protein alignment using DIAMOND. Nat Methods. 2015; 12:59-60. https://doi.org/10.1038/nmeth.3176.

[24] Corriero A, Gadaleta RM, Puntillo F, Inchingolo F, Moschetta A, Brienza N. The central role of the gut in intensive care. Crit Care. 2022; 26:379. https://doi.org/10.1186/s13054-022-04259-8.

[25] Schlechte J, Zucoloto AZ, Yu I, Doig CJ, Dunbar MJ, McCoy KD, et al. Dysbiosis of a microbiota-immune metasystem in critical illness is associated with nosocomial infections. Nat Med. 2023; 29:1017-1027. https://doi.org/10.1038/s41591-023-02243-5.

[26] Pettigrew MM, Gent JF, Kong Y, Halpin AL, Pineles L, Harris AD, et al. Gastrointestinal microbiota disruption and risk of colonization with carbapenem-resistant Pseudomonas aeruginosa in intensive care unit patients. Clin Infect Dis. 2019; 69:604-13. https://doi.org/10.1093/cid/ciy936.

[27] Freedberg DE, Zhou MJ, Cohen ME, Annavajhala MK, Khan S, Moscoso DI, et al. Pathogen colonization of the gastrointestinal microbiome at intensive care unit admission and risk for subsequent death or infection. Intensive Care Med. 2018; 44:1203-11. https://doi.org/10.1007/s00134-018-5268-8.

[28] Buelow E, Bello González TDJ, Fuentes S, De Steenhuijsen Piters WAA, Lahti L, Bayjanov JR, et al. Comparative gut microbiota and resistome profiling of intensive care patients receiving selective digestive tract decontamination and healthy subjects. Microbiome. 2017; 5:88. https://doi.org/10.1186/s40168-017-0309-z.

[29] Yelin I, Flett KB, Merakou C, Mehrotra P, Stam J, Snesrud E, et al. Genomic and epidemiological evidence of bacterial transmission from probiotic capsule to blood in ICU patients. Nat Med. 2019; 25:1728-32. https://doi.org/10.1038/s41591-019-0626-9.

[30] Litton E, Anstey M, Broadhurst D, Chapman A, Currie A, Ferrier J, et al. Early and sustained lactobacillus plantarum probiotic therapy in critical illness: the randomised, placebo-controlled, restoration of gut microflora in critical illness trial (ROCIT). Intensive Care Med. 2021; 47:307-15. https://doi.org/10.1007/s00134-020-06322-w.

[31] Johnstone J, Meade M, Lauzier F, Marshall J, Duan E, Dionne J, et al. Effect of probiotics on incident ventilator-associated pneumonia in critically ill patients. JAMA. 2021; 326:1024-33. https://doi.org/10.1001/jama.2021.13355.

[32] Sharif S, Greer A, Skorupski C, Hao Q, Johnstone J, Dionne JC, et al. Probiotics in critical illness: a systematic review and meta-analysis of randomized controlled trials. Crit Care Med. 2022; 50:1175-86.

[33] van Minnen LP, Timmerman HM, Lutgendorff F, Verheem A, Harmsen W, Konstantinov SR, et al. Modification of intestinal flora with multispecies probiotics reduces bacterial translocation and improves clinical course in a rat model of acute pancreatitis. Surgery. 2007; 141:470-80.

[34] Lutgendorff F, Nijmeijer RM, Sandström PA, Trulsson LM, Magnusson KE, Timmerman HM, et al. Probiotics prevent intestinal barrier dysfunction in acute pancreatitis in rats via induction of ileal mucosal glutathione biosynthesis. PLoS One. 2009; 4:e4512. https://doi.org/10.1371/journal.pone.0004512.

[35] Pan LL, Niu W, Fang X, Liang W, Li H, Chen W, et al. Clostridium butyricum strains suppress experimental acute pancreatitis by maintaining intestinal homeostasis. Molecular nutrition & food research. Wiley online. Library. 2019; 63:1801419.

[36] Karakan T, Ergun M, Dogan I, Cindoruk M, Unal S. Comparison of early enteral nutrition in severe acute pancreatitis with prebiotic fiber supplementation versus standard enteral solution: a prospective randomized double-blind study. World J Gastroenterol: WJG. 2007; 13:2733.

[37] Leonardi I, Gao IH, Lin WY, Allen M, Li XV, Fiers WD, et al. Mucosal fungi promote gut barrier function and social behavior via type 17 immunity. Cell. 2022; 185:831-846.e14. https://doi.org/10.1016/j.cell.2022.01.017.

[38] Li XV, Leonardi I, Putzel GG, Semon A, Fiers WD, Kusakabe T, et al. Immune regulation by fungal strain diversity in inflammatory bowel disease. Nature. 2022; 603:672-8.